---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-001516"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2023-01-25T23:59:59+00:00"
generated_at: "2026-06-20T09:38:46.916288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q4 sales $10.1B, full-year GAAP EPS $3.91; guides FY23 adj. EPS $4.30-4.50

## Summary
- Q4 GAAP diluted EPS $0.59; adjusted diluted EPS $1.03; full-year GAAP EPS $3.91, adjusted $5.34.
- Full-year sales flat at $43.7B; organic growth 6.4%; COVID-testing sales $8.4B vs. $7.7B in 2021.
- 2023 guidance: GAAP EPS $3.05-3.25, adjusted EPS $4.30-4.50; organic growth ex-COVID high-single digits.
- Quarterly dividend of $0.51 per share declared, payable Feb. 15, 2023; 51 consecutive years of increases.
- FreeStyle Libre Q4 sales ~$1.1B; U.S. growth >40%; FDA approvals for Navitor TAVI and Eterna SCS.

## SEC filing metadata
- accession: 0001628280-23-001516
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2023-01-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/abt-20230125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-001516
- JSON: https://secwatch.observer/filing/0001628280-23-001516.json
- Plain text: https://secwatch.observer/filing/0001628280-23-001516.txt

## Key facts
- Earnings Releases
  ABBOTT LABORATORIES reported full year 2022 results: revenue $43.7 billion, EPS $3.91. Guidance initiated.
  - Period: full year 2022
  - Revenue: $43.7 billion
  - EPS: $3.91
  - Guidance: initiated
  - Result: reported results
  source text: --- News Release Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook – Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billion – Full-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percent – Full-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34 – Continues to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm
- Earnings Releases
  ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2022 results: revenue $10.1 billion, EPS $0.59.
  - Period: the fourth quarter ended Dec. 31, 2022
  - Revenue: $10.1 billion
  - EPS: $0.59
  - Result: reported results
  source text: Abbott today announced financial results for the fourth quarter ended Dec. 31, 2022. • Fourth-quarter sales of $10.1 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828023001516/0001628280-23-001516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.